Top

BMC Cancer

Published in:

Open Access 01-12-2013 | Research article

Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review

Authors: Frank Kunath, Bastian Keck, Gerta Rücker, Edith Motschall, Bernd Wullich, Gerd Antes, Joerg J Meerpohl

Published in: BMC Cancer | Issue 1/2013

Abstract

Background

There is currently no consensus regarding the optimal timing for androgen suppression therapy in patients with prostate cancer that have undergone local therapy with curative intent but are proven to have node-positive disease without signs of distant metastases at the time of local therapy. The objective of this systematic review was to determine the benefits and harms of early (at the time of local therapy) versus deferred (at the time of clinical disease progression) androgen suppression therapy for patients with node-positive prostate cancer after local therapy.

Methods

The protocol was registered prospectively (CRD42011001221; http://www.crd.york.ac.uk/PROSPERO). We searched the MEDLINE, EMBASE, and CENTRAL databases, as well as reference lists, the abstracts of three major conferences, and three trial registers, to identify randomized controlled trials (search update 04/08/2012). Two authors independently screened the identified articles, assessed trial quality, and extracted data.

Results

Four studies including 398 patients were identified for inclusion. Early androgen suppression therapy lead to a significant decrease in overall mortality (HR 0.62, 95% CI 0.46-0.84), cancer-specific mortality (HR 0.34, 95% CI 0.18-0.64), and clinical progression at 3 or 9 years (RR 0.29, 95% CI 0.16-0.52 at 3 years and RR 0.49, 95% CI 0.36-0.67 at 9 years). One study showed an increase of adverse effects with early androgen suppression therapy. All trials had substantial methodological limitations.

Conclusions

The data available suggest an improvement in survival and delayed disease progression but increased adverse events for patients with node-positive prostate cancer after local therapy treated with early androgen suppression therapy versus deferred androgen suppression therapy. However, quality of data is low. Randomized controlled trials with blinding of outcome assessment, planned to determine the timing of androgen suppression therapy in node-positive prostate cancer using modern diagnostic imaging modalities, biochemical testing, and standardized follow-up schedules should be conducted to confirm these findings.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.CrossRefPubMed

Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA: Annual Report to the Nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012, 118 (9): 2338-2366. 10.1002/cncr.27514.CrossRefPubMedPubMedCentral

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011, 59 (1): 61-71. 10.1016/j.eururo.2010.10.039.CrossRefPubMed

Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002, 167 (2 Pt 2): 948-951. discussion 952CrossRefPubMed

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011, 59 (4): 572-583. 10.1016/j.eururo.2011.01.025.CrossRefPubMed

Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998, 17 (24): 2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.CrossRefPubMed

Williamson PR, Smith CT, Hutton JL, Marson AG: Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002, 21 (22): 3337-3351. 10.1002/sim.1303.CrossRefPubMed

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 8: 16-10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral

Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol. 2005, 23 (4): 800-807. 10.1200/JCO.2005.08.141.CrossRefPubMed

10.

Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85–31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1997, 38 (5): 931-939. 10.1016/S0360-3016(97)00288-5.CrossRefPubMed

11.

Granfors T, Modig H, Damber J-E, Tomic R: Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol. 2006, 176 (2): 544-547. 10.1016/j.juro.2006.03.092.CrossRefPubMed

12.

Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998, 159 (6): 2030-2034. 10.1016/S0022-5347(01)63235-X.CrossRefPubMed

13.

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999, 341 (24): 1781-1788. 10.1056/NEJM199912093412401.CrossRefPubMed

14.

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, Trump D: Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. J Clin Oncol. 2004, 22 (14s): 4570-

15.

Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D, Eastern Cooperative Oncology Group study EST: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006, 7 (6): 472-479. 10.1016/S1470-2045(06)70700-8.CrossRefPubMed

16.

Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM: Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology. 2004, 63 (5): 928-933. 10.1016/j.urology.2004.02.011.CrossRefPubMed

17.

Iversen P, Wirth MP, See WA, McLeod DG, Morris T, Armstrong J: The influence of nodal status on progression outcomes in patients with prostate cancer: Data from Early Prostate Cancer program at 7.4 years. J Clin Oncol. 2006, 24 (18S): abstract 4628-

18.

Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Schmid HP, van der Kwast TH, Wiegel T, Zattoni F: Guidelines on Prostate Cancer [online]. European Association of Urology. 2010, http://www.uroweb.org/guidelines/copyright-and-republication/how-to-reference-the-eau-guidelines/ (downloaded on 13/03/2012)

19.

Anscher MS, Prosnitz LR: Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology. 1992, 39 (1): 39-43. 10.1016/0090-4295(92)90038-X.CrossRefPubMed

20.

Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F: Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009, 55 (2): 261-270. 10.1016/j.eururo.2008.09.043.CrossRefPubMed

21.

Zincke H, Utz DC, Thule PM, Taylor WF: Treatment options for patients with stage D1 (T0–3, N1–2, M0) adenocarcinoma of prostate. Urology. 1987, 30 (4): 307-315. 10.1016/0090-4295(87)90290-1.CrossRefPubMed

22.

Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM: Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology. 2007, 70 (4): 723-727. 10.1016/j.urology.2007.05.014.CrossRefPubMed

23.

Myers RP, Zincke H, Fleming TR, Farrow GM, Furlow WL, Utz DC: Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. J Urol. 1983, 130 (1): 99-101.PubMed

24.

Kramolowsky EV: The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol. 1988, 139 (6): 1242-1244.PubMed

25.

Feyaerts A, Stainier L, Nollevaux MC, De Groote P, Lorge F, Opsomer R, Wese FX, Cosyns JP, Van Cangh P: [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)]. Acta Urol Belg. 1998, 66 (1): 1-6.PubMed

26.

Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL: Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?. BJU Int. 2007, 99 (2): 321-325. 10.1111/j.1464-410X.2006.06648.x.CrossRefPubMed

27.

de Kernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol. 1990, 144 (3): 700-703.

28.

Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K: Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009, 27 (1): 100-105.CrossRefPubMed

29.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML: Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007, 178 (3 Pt 1): 864-870. discussion 870–861CrossRefPubMed

30.

Cheng CW, Bergstralh EJ, Zincke H: Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer. 1993, 71 (3 Suppl): 996-1004.CrossRefPubMed

31.

Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM: Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol. 1992, 147 (3 Pt 2): 910-915.PubMed

32.

Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology. 1989, 33 (5 Suppl): 27-36.CrossRefPubMed

33.

Seay TM, Blute ML, Zincke H: Long-term outcome in patients with pTxN + adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998, 159 (2): 357-364. 10.1016/S0022-5347(01)63917-X.CrossRefPubMed

34.

Taylor LG, Canfield SE, Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009, 115 (11): 2388-2399. 10.1002/cncr.24283.CrossRefPubMed

35.

Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns CF, Navani S: Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis. 2007, 10 (1): 87-93. 10.1038/sj.pcan.4500916.CrossRefPubMed

36.

van Andel G, Kurth KH: The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol. 2003, 44 (2): 209-214. 10.1016/S0302-2838(03)00208-2.CrossRefPubMed

37.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol. 2009, 27 (1): 92-99.CrossRefPubMed

38.

Wiegand LR, Hernandez M, Pisters LL, Spiess PE: Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int. 2011, 107 (8): 1238-1242. 10.1111/j.1464-410X.2010.09657.x.CrossRefPubMed

39.

Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001, 58 (6): 843-848. 10.1016/S0090-4295(01)01441-8.CrossRefPubMed

40.

Miyamae K, Kitani K, Miyamoto K, Hamada S, Kawano T, Maehara A, Otsuka Y, Otsuka T, Hamada Y: [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy]. Nippon Hinyokika Gakkai Zasshi. 2009, 100 (5): 570-575.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/131/prepub

Title: Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review
Authors: Frank Kunath
Bastian Keck
Gerta Rücker
Edith Motschall
Bernd Wullich
Gerd Antes
Joerg J Meerpohl
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-13-131

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer

Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study

Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells

The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer